Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohortCarmelo Gurnari, Maria Teresa Voso, Elena Crisà et al.|American Journal of Hematology|2023Cited by 43
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic ImplicationsErika Morsia, Serena Rupoli, Elena Torre et al.|International Journal of Molecular Sciences|2022Cited by 22
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest InsightsErika Morsia, Serena Rupoli, Elena Torre et al.|International Journal of Molecular Sciences|2024Cited by 7